vs

Side-by-side financial comparison of Arlo Technologies, Inc. (ARLO) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Arlo Technologies, Inc. is the larger business by last-quarter revenue ($141.3M vs $74.7M, roughly 1.9× Health Catalyst, Inc.). Arlo Technologies, Inc. runs the higher net margin — 4.1% vs -121.9%, a 126.0% gap on every dollar of revenue. On growth, Arlo Technologies, Inc. posted the faster year-over-year revenue change (16.2% vs -6.2%). Over the past eight quarters, Arlo Technologies, Inc.'s revenue compounded faster (6.7% CAGR vs -0.0%).

Arlo Technologies is an American company that makes wireless surveillance cameras. Prior to an initial public offering (IPO) on the New York Stock Exchange in August 2018, Arlo was a brand of such products by Netgear, which retained majority control after the IPO.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

ARLO vs HCAT — Head-to-Head

Bigger by revenue
ARLO
ARLO
1.9× larger
ARLO
$141.3M
$74.7M
HCAT
Growing faster (revenue YoY)
ARLO
ARLO
+22.4% gap
ARLO
16.2%
-6.2%
HCAT
Higher net margin
ARLO
ARLO
126.0% more per $
ARLO
4.1%
-121.9%
HCAT
Faster 2-yr revenue CAGR
ARLO
ARLO
Annualised
ARLO
6.7%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARLO
ARLO
HCAT
HCAT
Revenue
$141.3M
$74.7M
Net Profit
$5.8M
$-91.0M
Gross Margin
46.4%
Operating Margin
3.3%
-115.3%
Net Margin
4.1%
-121.9%
Revenue YoY
16.2%
-6.2%
Net Profit YoY
218.6%
-340.3%
EPS (diluted)
$0.06
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARLO
ARLO
HCAT
HCAT
Q4 25
$141.3M
$74.7M
Q3 25
$139.5M
$76.3M
Q2 25
$129.4M
$80.7M
Q1 25
$119.1M
$79.4M
Q4 24
$121.6M
$79.6M
Q3 24
$137.7M
$76.4M
Q2 24
$127.4M
$75.9M
Q1 24
$124.2M
$74.7M
Net Profit
ARLO
ARLO
HCAT
HCAT
Q4 25
$5.8M
$-91.0M
Q3 25
$6.9M
$-22.2M
Q2 25
$3.1M
$-41.0M
Q1 25
$-835.0K
$-23.7M
Q4 24
$-4.9M
$-20.7M
Q3 24
$-4.4M
$-14.7M
Q2 24
$-11.6M
$-13.5M
Q1 24
$-9.6M
$-20.6M
Gross Margin
ARLO
ARLO
HCAT
HCAT
Q4 25
46.4%
Q3 25
40.5%
52.6%
Q2 25
44.9%
Q1 25
44.3%
Q4 24
36.9%
Q3 24
35.2%
47.5%
Q2 24
36.8%
Q1 24
38.1%
Operating Margin
ARLO
ARLO
HCAT
HCAT
Q4 25
3.3%
-115.3%
Q3 25
0.6%
-22.9%
Q2 25
1.5%
-46.0%
Q1 25
-1.2%
-25.4%
Q4 24
-5.0%
-22.0%
Q3 24
-4.0%
-17.9%
Q2 24
-10.0%
-20.8%
Q1 24
-8.5%
-30.5%
Net Margin
ARLO
ARLO
HCAT
HCAT
Q4 25
4.1%
-121.9%
Q3 25
4.9%
-29.1%
Q2 25
2.4%
-50.8%
Q1 25
-0.7%
-29.9%
Q4 24
-4.0%
-26.0%
Q3 24
-3.2%
-19.3%
Q2 24
-9.1%
-17.8%
Q1 24
-7.8%
-27.6%
EPS (diluted)
ARLO
ARLO
HCAT
HCAT
Q4 25
$0.06
$-1.29
Q3 25
$0.06
$-0.32
Q2 25
$0.03
$-0.59
Q1 25
$-0.01
$-0.35
Q4 24
$-0.05
$-0.33
Q3 24
$-0.04
$-0.24
Q2 24
$-0.12
$-0.23
Q1 24
$-0.10
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARLO
ARLO
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$146.4M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$127.8M
$245.8M
Total Assets
$310.5M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARLO
ARLO
HCAT
HCAT
Q4 25
$146.4M
$95.7M
Q3 25
$86.0M
$91.5M
Q2 25
$71.2M
$97.3M
Q1 25
$84.0M
$342.0M
Q4 24
$82.0M
$392.0M
Q3 24
$77.0M
$387.3M
Q2 24
$62.9M
$308.3M
Q1 24
$62.1M
$327.8M
Total Debt
ARLO
ARLO
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
ARLO
ARLO
HCAT
HCAT
Q4 25
$127.8M
$245.8M
Q3 25
$129.2M
$331.9M
Q2 25
$118.3M
$347.5M
Q1 25
$103.4M
$376.8M
Q4 24
$100.9M
$365.2M
Q3 24
$96.9M
$355.0M
Q2 24
$99.3M
$357.0M
Q1 24
$99.9M
$357.2M
Total Assets
ARLO
ARLO
HCAT
HCAT
Q4 25
$310.5M
$502.6M
Q3 25
$350.9M
$587.1M
Q2 25
$319.7M
$616.2M
Q1 25
$296.6M
$891.5M
Q4 24
$298.4M
$858.9M
Q3 24
$312.4M
$813.0M
Q2 24
$295.8M
$691.7M
Q1 24
$289.8M
$695.1M
Debt / Equity
ARLO
ARLO
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARLO
ARLO
HCAT
HCAT
Operating Cash FlowLast quarter
$19.8M
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
3.43×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARLO
ARLO
HCAT
HCAT
Q4 25
$19.8M
$9.9M
Q3 25
$19.2M
$-464.0K
Q2 25
$8.8M
$-9.0M
Q1 25
$30.9M
$280.0K
Q4 24
$6.7M
$-3.5M
Q3 24
$18.4M
$6.2M
Q2 24
$6.5M
$1.6M
Q1 24
$19.8M
$10.3M
Free Cash Flow
ARLO
ARLO
HCAT
HCAT
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$28.1M
$-390.0K
Q4 24
$5.6M
$-3.9M
Q3 24
$17.4M
$5.5M
Q2 24
$6.2M
$1.3M
Q1 24
$19.4M
$10.1M
FCF Margin
ARLO
ARLO
HCAT
HCAT
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
23.6%
-0.5%
Q4 24
4.6%
-4.9%
Q3 24
12.6%
7.2%
Q2 24
4.8%
1.7%
Q1 24
15.7%
13.5%
Capex Intensity
ARLO
ARLO
HCAT
HCAT
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
2.4%
0.8%
Q4 24
0.9%
0.5%
Q3 24
0.7%
0.9%
Q2 24
0.2%
0.4%
Q1 24
0.3%
0.3%
Cash Conversion
ARLO
ARLO
HCAT
HCAT
Q4 25
3.43×
Q3 25
2.79×
Q2 25
2.83×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARLO
ARLO

Subscriptions And Services$89.4M63%
Products$51.9M37%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons